Hormone shot before embryo transfer may boost pregnancy chances in severe endometriosis

NCT ID NCT07696351

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests whether giving two injections of a long-acting hormone (GnRH-a) before standard hormone therapy can improve pregnancy rates in women with deep infiltrating endometriosis undergoing their first frozen embryo transfer. The hormone pretreatment aims to suppress endometriosis lesions and reduce inflammation, potentially making the womb lining more receptive. Participants are randomly assigned to receive either the hormone pretreatment plus standard therapy or standard therapy alone, and the main outcome is the rate of clinical pregnancy detected by ultrasound.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Triptorelin (GnRH agonist)
What this could lead to
If successful, this approach could increase the chance of pregnancy after frozen embryo transfer for women with deep infiltrating endometriosis.
What could go wrong
This is a mid-stage trial with 120 participants, so results may not apply to all patients. GnRH agonists can cause side effects like hot flashes and mood changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEEP INFILTRATING ENDOMETRIOSIS (DIE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • The Affiliated Drum Tower Hospital of Nanjing University Medical School

    RECRUITING

    Nanjing, Jiangsu, 216000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.